← 返回

胰腺癌中线粒体 UQCRC1 表达升高通过升高细胞外 ATP 损害 NK 细胞的抗肿瘤免疫

英文原题:Increased Expression of Mitochondrial UQCRC1 in Pancreatic Cancer Impairs Antitumor Immunity of Natural Killer Cells via Elevating Extracellular ATP.

查看英文原题

Increased Expression of Mitochondrial UQCRC1 in Pancreatic Cancer Impairs Antitumor Immunity of Natural Killer Cells via Elevating Extracellular ATP.

PubMed 2022/06/13(内容时间) Front Oncol Q2 · IF 3.4(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

中文摘要

胰腺癌(PC)是一种致死率极高的恶性肿瘤,其肿瘤微环境(TME)具有强烈免疫抑制性。研究团队此前报道,线粒体复合物III关键组分泛醌-细胞色素c还原酶核心蛋白I(UQCRC1)在PC中普遍上调,可产生细胞外ATP(eATP)并促进PC进展。

本研究探讨UQCRC1致癌作用是否通过影响TME中的自然杀伤(NK)细胞实现。结果显示,PC细胞过表达UQCRC1会抑制NK细胞细胞毒性及其向PC的浸润;敲低UQCRC1则增强NK细胞细胞毒性和趋化能力。皮下小鼠模型中的过继NK细胞治疗和人PC标本CIBERSORTx分析均证实,UQCRC1对NK细胞产生免疫抑制作用。UQCRC1诱导的NK细胞损伤由eATP及其代谢产物腺苷分别通过P2Y11R和A2AR介导。

机制上,UQCRC1/eATP轴降低癌细胞趋化因子CCL5表达,并改变NK-92MI细胞活化受体DNAM-1与抑制受体CD96的平衡,导致趋化降低和NK-92MI细胞耗竭。

综上,本研究为癌细胞能量代谢变化重塑TME、阻碍NK细胞免疫监视提供了证据,也提示靶向UQCRC1可能成为PC免疫治疗的联合策略。

展开英文摘要原文

Pancreatic cancer (PC) is one of the most lethal malignancies characterized by a highly immunosuppressive tumor microenvironment (TME). Previously, we have reported that ubiquinol-cytochrome c reductase core protein I (UQCRC1), a key component of mitochondrial complex III, is generally upregulated in PC and produces extracellular ATP (eATP) to promote PC progression.

Here, we sought to investigate whether the oncogenic property of UQCRC1 is generated through its effects on natural killer (NK) cells in the TME.

We found that UQCRC1 overexpression in PC cells inhibited cytotoxicity of NK cells, as well as the infiltration of NK cells toward PC, whereas knockdown of UQCRC1 enhanced the cytotoxicity and chemotaxis of NK cells. Adoptive NK cell therapy in the subcutaneous mouse model and CIBERSORTx analysis with human PC specimens confirmed UQCRC1 elicited immunosuppressive effects on NK cells. Such UQCRC1-induced impairment of NK cells was mediated by eATP and its metabolite adenosine via P2Y11R and A 2A R, respectively.

Mechanistically, we found the UQCRC1/eATP axis reduced the expression of chemokine CCL5 in cancer cells and altered the balance of activating receptor DNAM-1 and inhibitory receptor CD96 on NK-92MI cells, resulting in decreased chemotaxis and exhausted phenotype of NK-92MI cells. Taken together, our study provides the evidence to support a novel mechanism by which energy metabolism change in cancer cells remodels the TME and impedes NK cell surveillance. It also suggests that targeting UQCRC1 may be a potential combined strategy for PC immunotherapy.

论文信息

作者
Cong H、Gao J、Wang Q、Du M、Li H、Li Q、Li J、Liang Y
单位
State Key Laboratory of Oncogenes and Related Genes, Shanghai Cancer Institute, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.China
期刊
Frontiers in oncology2022
原文标识
PubMed 35769718 · DOI 10.3389/fonc.2022.872017